Search Results - "Ramalingam, Suresh S"

Cancer Turns 75 by Ramalingam, Suresh S.

“…Celebrating 75 years of publication, Cancer continues to serve as a beacon for scientific research that is fundamental to achieving cures for cancer. Heading…”
Get full text

Lung cancer: New biological insights and recent therapeutic advances by Ramalingam, Suresh S., Owonikoko, Taofeek K., Khuri, Fadlo R.

“…Approximately 1.6 million new cases of lung cancer are diagnosed each year throughout the world. In many countries, the mortality related to lung cancer…”
Get full text

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer by Ramalingam, Suresh S, Yang, James C-H, Lee, Chee Khoon, Kurata, Takayasu, Kim, Dong-Wan, John, Thomas, Nogami, Naoyuki, Ohe, Yuichiro, Mann, Helen, Rukazenkov, Yuri, Ghiorghiu, Serban, Stetson, Daniel, Markovets, Aleksandra, Barrett, J Carl, Thress, Kenneth S, Jänne, Pasi A

“…Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety…”
Get full text

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers by Ready, Neal, Hellmann, Matthew D, Awad, Mark M, Otterson, Gregory A, Gutierrez, Martin, Gainor, Justin F, Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela, Brahmer, Julie, Rabinowitz, Ian, Reddy, Pavan S, Chesney, Jason, Orcutt, James, Spigel, David R, Reck, Martin, O'Byrne, Kenneth John, Paz-Ares, Luis, Hu, Wenhua, Zerba, Kim, Li, Xuemei, Lestini, Brian, Geese, William J, Szustakowski, Joseph D, Green, George, Chang, Han, Ramalingam, Suresh S

“…CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of…”
Get full text

Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions by Marullo, Rossella, Werner, Erica, Degtyareva, Natalya, Moore, Bryn, Altavilla, Giuseppe, Ramalingam, Suresh S, Doetsch, Paul W

“…Cisplatin is one of the most effective and widely used anticancer agents for the treatment of several types of tumors. The cytotoxic effect of cisplatin is…”
Get full text

Personalized therapy for lung cancer: striking a moving target by Pakkala, Suchita, Ramalingam, Suresh S

“…Molecular targeted therapy heralded a new era for the treatment of patients with oncogene-driven advanced-stage non-small-cell lung cancer (NSCLC). Molecular…”
Get full text

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer by Jänne, Pasi A, Yang, James Chih-Hsin, Kim, Dong-Wan, Planchard, David, Ohe, Yuichiro, Ramalingam, Suresh S, Ahn, Myung-Ju, Kim, Sang-We, Su, Wu-Chou, Horn, Leora, Haggstrom, Daniel, Felip, Enriqueta, Kim, Joo-Hang, Frewer, Paul, Cantarini, Mireille, Brown, Kathryn H, Dickinson, Paul A, Ghiorghiu, Serban, Ranson, Malcolm

“…AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced…”
Get full text

Immune checkpoint inhibitors in advanced non–small cell lung cancer by Assi, Hazem I., Kamphorst, Alice O., Moukalled, Nour M., Ramalingam, Suresh S.

“…The emergence of immune checkpoint inhibitors for the treatment of cancer has led to major changes to the therapeutic landscape of lung cancer. Improvements in…”
Get full text

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature by Pillai, Rathi N., Behera, Madhusmita, Owonikoko, Taofeek K., Kamphorst, Alice O., Pakkala, Suchita, Belani, Chandra P., Khuri, Fadlo R., Ahmed, Rafi, Ramalingam, Suresh S.

“…BACKGROUND Monoclonal antibodies against programmed cell death protein 1 (PD‐1) and programmed death ligand 1 (PD‐L1) are effective therapies in patients with…”
Get full text

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component by Yang, James Chih-Hsin, Ahn, Myung-Ju, Kim, Dong-Wan, Ramalingam, Suresh S, Sequist, Lecia V, Su, Wu-Chou, Kim, Sang-We, Kim, Joo-Hang, Planchard, David, Felip, Enriqueta, Blackhall, Fiona, Haggstrom, Daniel, Yoh, Kiyotaka, Novello, Silvia, Gold, Kathryn, Hirashima, Tomonori, Lin, Chia-Chi, Mann, Helen, Cantarini, Mireille, Ghiorghiu, Serban, Jänne, Pasi A

“…Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing ( EGFRm)…”
Get full text

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset by Ohe, Yuichiro, Imamura, Fumio, Nogami, Naoyuki, Okamoto, Isamu, Kurata, Takayasu, Kato, Terufumi, Sugawara, Shunichi, Ramalingam, Suresh S, Uchida, Hirohiko, Hodge, Rachel, Vowler, Sarah L, Walding, Andrew, Nakagawa, Kazuhiko

“…In the FLAURA trial Japanese subset, osimertinib significantly improved median PFS versus standard-of-care (gefitinib) in patients with previously untreated…”
Get full text

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline by Rudin, Charles M, Ismaila, Nofisat, Hann, Christine L, Malhotra, Narinder, Movsas, Benjamin, Norris, Kim, Pietanza, M Catherine, Ramalingam, Suresh S, Turrisi, 3rd, Andrew T, Giaccone, Giuseppe

“…The American College of Chest Physicians (ACCP) produced an evidence-based guideline on treatment of patients with small-cell lung cancer (SCLC). Because of…”
Get full text

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium by Pillai, Rathi N., Behera, Madhusmita, Berry, Lynne D., Rossi, Mike R., Kris, Mark G., Johnson, Bruce E., Bunn, Paul A., Ramalingam, Suresh S., Khuri, Fadlo R.

“…BACKGROUND Human epidermal growth factor receptor 2 (HER2) mutations have been reported in lung adenocarcinomas. Herein, the authors describe the prevalence,…”
Get full text

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer by Chmielecki, Juliann, Gray, Jhanelle E., Cheng, Ying, Ohe, Yuichiro, Imamura, Fumio, Cho, Byoung Chul, Lin, Meng-Chih, Majem, Margarita, Shah, Riyaz, Rukazenkov, Yuri, Todd, Alexander, Markovets, Aleksandra, Barrett, J. Carl, Hartmaier, Ryan J., Ramalingam, Suresh S.

“…Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M…”
Get full text

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100 by Dy, Grace K, Govindan, Ramaswamy, Velcheti, Vamsidhar, Falchook, Gerald S, Italiano, Antoine, Wolf, Jürgen, Sacher, Adrian G, Takahashi, Toshiaki, Ramalingam, Suresh S, Dooms, Christophe, Kim, Dong-Wan, Addeo, Alfredo, Desai, Jayesh, Schuler, Martin, Tomasini, Pascale, Hong, David S, Lito, Piro, Tran, Qui, Jones, Simon, Anderson, Abraham, Hindoyan, Antreas, Snyder, Wendy, Skoulidis, Ferdinandos, Li, Bob T

“…JCO In the longest follow-up, to our knowledge, for a KRAS inhibitor, we assessed the long-term efficacy, safety, and biomarkers of sotorasib in patients with…”
Get full text

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment by Shi, Puyu, You, You-Take, Zhang, Guojing, Yao, Weilong, Yue, Ping, Li, Yikun, Kanteti, Rajani, Riehm, Jacob, Salgia, Ravi, Owonikoko, Taofeek K, Ramalingam, Suresh S, Chen, Mingwei, Sun, Shi-Yong

“…Highlights • Met amplification and protein hyperactivation is a resistance mechanism to both 1st and 3rd generation EGFR inhibitors • Met inhibition…”
Get full text

The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer by Smeltzer, Matthew P, Wynes, Murry W, Lantuejoul, Sylvie, Soo, Ross, Ramalingam, Suresh S, Varella-Garcia, Marileila, Meadows Taylor, Meghan, Richeimer, Kristin, Wood, Kelsey, Howell, Kristen E, Dalurzo, Mercedes Lilana, Felip, Enriqueta, Hollenbeck, Gina, Kerr, Keith, Kim, Edward S, Mathias, Clarissa, Pacheco, Jose, Postmus, Pieter, Powell, Charles, Tsuboi, Masahiro, Wistuba, Ignacio I, Wakelee, Heather A, Belani, Chandra P, Scagliotti, Giorgio V, Hirsch, Fred R

“…Access to targeted therapies for lung cancer depends on the accurate identification of patients' biomarkers through molecular testing. The International…”
Get more information

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial by Chmielecki, Juliann, Mok, Tony, Wu, Yi-Long, Han, Ji-Youn, Ahn, Myung-Ju, Ramalingam, Suresh S., John, Thomas, Okamoto, Isamu, Yang, James Chih-Hsin, Shepherd, Frances A., Bulusu, Krishna C., Laus, Gianluca, Collins, Barbara, Barrett, J. Carl, Hartmaier, Ryan J., Papadimitrakopoulou, Vassiliki

“…Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M…”
Get full text

mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection by Ando, Satomi, Perkins, Charles M, Sajiki, Yamato, Chastain, Chase, Valanparambil, Rajesh M, Wieland, Andreas, Hudson, William H, Hashimoto, Masao, Ramalingam, Suresh S, Freeman, Gordon J, Ahmed, Rafi, Araki, Koichi

“…T cell exhaustion is a state of T cell dysfunction associated with expression of programmed death 1 (PD-1). Exhausted CD8+ T cells are maintained by…”
Get full text

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer by Gerber, David E., Camidge, D. Ross, Morgensztern, Daniel, Cetnar, Jeremey, Kelly, Ronan J., Ramalingam, Suresh S., Spigel, David R., Jeong, Woondong, Scaglioni, Pier P., Zhang, Song, Li, Marilyn, Weaver, David T., Vaikus, Louis, Keegan, Mitchell, Horobin, Joanna C., Burns, Timothy F.

“…•KRAS mutant non-small cell lung cancer (NSCLC) is a major unmet clinical need.•RHOA-focal adhesion kinase (FAK) pathway is a signaling axis for KRAS mutant…”
Get full text